Seven-Probe Fiber Detector for Time-Resolved Source Tracking in HDR-Brachytherapy: Experimental Evaluation

2025

Read Seven-Probe Fiber Detector for Time-Resolved Source Tracking in HDR-Brachytherapy: Experimental Evaluation (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2506-16124.txt.

Introduction

Mathieu Gonod and co-authors test a hair-thin detector that tracks a radioactive source during radiation therapy. In high-dose-rate brachytherapy, a source dwells at spots inside the body, and a positioning slip can overdose healthy tissue. The detector packs seven tiny scintillator cells onto optical fibers in a bundle under half a millimeter wide. Each cell flashes as the source passes, and a camera reads the pattern of flashes.

The team ran the device against a standard treatment machine over 4,040 dwell positions. Gaps ran from ten to thirty-six millimeters, and dwell times from a tenth of a second to nearly twenty. It found 99.5 percent of the positions, with average placement errors near two tenths of a millimeter. Nearly all readings fell within the one-millimeter safety line. The few failures clustered at the first dwell of each run, traced to the machine itself.

Catalog record

YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE53 KB
VERSION1.0
LICENSEhttp://creativecommons.org/licenses/by/4.0/
RIGHTSCC BY
SOURCEarXiv

Source: https://arxiv.org/abs/2506-16124

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Seven-Probe Fiber Detector for Time-Resolved Source Tracking in HDR-Brachytherapy: Experimental Evaluation Abstract Background: In vivo dosimetry (IVD) is increasingly recognized as a critical tool for verifying treatment delivery in HDR-brachytherapy (HDR-BT). Time-resolved techniques, such as source tracking, enables real-time error detection and reduces uncertainties in dose delivery. An ideal IVD system must accurately track the source across extended volumes along the source’s travel range and measure dwell times as short as fractions of a second. Purpose: This study evaluates a compact biocompatible Seven-probe Scintillator Detector (7SD) for monitoring HDR-BT treatment sequences across a range of dwell times and source-probe spacings representative of most HDR-BT techniques. The capability of the 7SD to detect source insertion errors is also assessed. Methods: The SSD comprises seven detection cells made of Gd 2 O 2 S:Tb, each measuring 0.28 ± \pm 0.02 mm in diameter and 0.43 ± \pm 0.02 mm in length, coupled to the microstructured tips of silica optical fibers (110-micron diameter). The probes, spaced 15 mm apart along the fiber axis, are organized into a bundle with a total diameter of less than 0.45 mm. The SSD was tested in a 50 × 50 × 30 50\times 50\times 30 cm 3 phantom using a MicroSelectron 9.1 Ci Ir-192 HDR afterloader connected to a BT stainless steel interstitial needle. Detection signals were acquired at 0.06-second intervals with an sCMOS camera equipped with a chromatic filter to eliminate spurious Cerenkov signals. The probe was experimentally calibrated in 2D without relying on the AAPM-TG43 formalism. Monitoring of dwell times and positions was performed by combining detection signals from all seven probes. Cytotoxicity tests were performed to confirm the biocompatibility of the 7SD Results: A total of 4,040 dwell positions were analyzed, covering source-probe spacings from 10 to 36 mm and a source travel range of 62 mm, with dwell times ranging from 0.1 to 19.5 s. The 7SD successfully identified 99.5% of the dwell positions. In cylindrical coordinates, the measured dwell positions deviated from the planned values by 0.224 ± \pm 0.155 mm (radial) and 0.077 ± \pm 0.181 mm (axial, source travel axis). The average deviation from planned dwell times was 0.006 ± \pm 0.061 s. 99.4% of the dwell positions were measured within the 1 mm reliability threshold. The remaining 0.6% of deviations consistently occurred at the initial dwell position of treatment sequences and appear to stem from a systematic source positioning error by the afterloader. Additionally, the detector accurately identified intentional needle mispositioning scenarios with sub-millimeter accuracy. Conclusions: A 7SD based on Gd 2 O 2 S:Tb, coupled with an sCMOS camera, demonstrates its suitability for time-resolved IVD in monitoring HDR-BT treatments. The 7SD substantially extends the monitoring volume along both the source’s axial path and the orthogonal radial direction, enabling accurate source tracking across treatment geometries representative of a wide variety of HDR-BT procedures. By detecting subtle afterloader malfunctions, the 7SD offers a precise and valuable means of evaluating the integrity of HDR-BT setups and procedures. Its high-resolution monitoring capabilities, confirmed biocompatibility, scalability, and compatibility with standard BT needles, catheters, and applicators underscore its potential for clinical implementation. Mathieu Gonod 1 , Miguel Angel Suarez 2 , Samir Laskri 3 , Gwenaël Rolin 4 , Karine Charriere 5 , Emmanuel Dordor 2 , Julien Crouzilles 3 , Thomas Lihoreau 6 , Lionel Pazart 5 , Jean-François Vinchant 3 , Léone Aubignac 1 and Thierry Grosjean* 2 1 Centre Georges François Leclerc (CGFL) - Dijon, France 2 Université Marie et Louis Pasteur, CNRS, Intitut FEMTO-ST, F-25000 Besançon, France 3 SEDI-ATI Fibres Optiques, 8 Rue Jean Mermoz, 91080 Évry-Courcouronnes, France 4 Université Marie et Louis Pasteur, CHU Besançon, UMR INSERM 1098 RIGHT, INSERM CIC1431, F-25000 Besançon, France 5 Université Marie et Louis Pasteur, CHU Besançon, UMR INSERM 1322 LINC, INSERM CIC1431, F-25000 Besançon, France 6 Université Marie et Louis Pasteur, CHU Besançon, Inserm CIC 1431, SINERGIES (UR4662), Tech4Health network (F-CRIN), F-25000 Besançon, France Version typeset August 8, 2026 *Author to whom correspondence should be addressed. email: [email protected] This is a sample note. I . Introduction High-Dose-Rate brachytherapy (HDR-BT) is a widely used radiotherapy technique that delivers high doses of radiation directly to the tumor while sparing surrounding healthy tissues. By using a temporary radioactive source, such as Iridium-192, positioned precisely within or near the tumor via applicators, catheters or needles, HDR BT achieves exceptional dose localization and treatment efficacy, making it a standard approach for cancers like prostate, cervical, and breast cancer. However, the high precision required in HDR BT also makes it susceptible to potential errors, such as incorrect source positioning, dwell time deviations, or applicator misplacement. These errors can lead to suboptimal dose delivery, resulting in reduced treatment efficacy or unintended exposure to healthy tissues. Given the high dose gradients involved and the proximity to critical organs, even small deviations can have significant clinical consequences. To address these challenges, in vivo dosimetry (IVD) has emerged as a promising tool for real-time verification of treatment delivery 1 , 2 . IVD enables direct monitoring of dose delivery during the procedure, providing immediate feedback on the treatment. This capability enhances patient safety by promptly identifying and correcting errors, ensuring optimal therapeutic outcomes. Integrating a scintillating cell with an optical fiber has shown considerable potential for developing compact detectors capable of time-resolved monitoring of dwell times, source positions, and/or delivered doses 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 . Moreover, by comparing measured dose values to those predicted by the treatment planning system (TPS), some source insertion errors have been successfully determined 10 . However, these single-probe detectors are constrained by a limited monitoring volume. Integrating multiple detection sites into a single BT needle or catheter is essential for expanding the monitoring volume along the source’s travel range, while enabling precise real-time treatment delivery monitoring in 2D or 3D. One approach utilizes arrays of independent fiber-based scintillation detectors 13 , 14 , 15 . Another strategy integrates up to three scintillation cells into a single optical fiber, enabling multiple detection points within a single BT needle or catheter to monitor dose deposition 16 , 17 , as well as dwell times and dwell positions 18 . These multipoint detectors have demonstrated time-resolved two-dimensional (2D) source tracking through triangulation techniques 18 . An evolution of this technology combines a three-point detector 18 with a single-probe dosimeter, each integrated into a distinct BT needle, to enable three-dimensional (3D) source position tracking through inter-probe triangulation 19 . Recent advancements in probe miniaturization have enabled the development of six-parallel-probe detectors compact enough to fit into BT needles or catheters 20 . These six-probe detectors provide a versatile platform for implementing diverse treatment monitoring strategies. Such a design streamlines in vivo detection architectures while improving detection accuracy. To date, evaluations of this miniaturized multiprobe approach have primarily focused on optimizing one-dimensional (1D) source tracking along the source displacement axis, with constant dwell times of 10 seconds. To fully realize the potential of multiprobe detectors, a comprehensive evaluation of their multidimensional monitoring capabilities under diverse BT conditions is required. This involves testing performance across a broader range of dwell times, down to 0.1 seconds, and source-probe spacings

Read the complete text